Literature DB >> 20309662

R72P polymorphism of TP53 in ulcerative colitis patients is associated with the incidence of colectomy, use of steroids and the presence of a positive family history.

Fatih Eren1, Mustafa Akkiprik, Ozlen Atuğ, Ozgür Sönmez, Gülgün Tahan, Filiz Ozdemir, Hülya Over Hamzaoğlu, Ciğdem Ataizi Celikel, Neşe Imeryüz, Erol Avşar, Ayşe Ozer.   

Abstract

P53 tumor suppressor protein is one of the pivotal regulators for genome integrity, cell cycle and apoptosis. The most commonly and extensively studied single nucleotide polymorphism (SNP) of p53 is Arg>Pro substitution on codon 72 (R72P). Although we know that the SNP has unique functional effects on the protein, its clinical significance is not clearly identified yet. Aim of the study was to access the relationship between R72P genotype distribution and clinical variables in patients with ulcerative colitis (UC) and colorectal cancer (CRC). Genomic DNA samples were extracted from 95 UC, 50 CRC, and 219 healthy controls. R72P genotype analysis was carried out with polymerase chain reaction following by restriction enzyme digestion. We observed that Pro allele carriage is a strong risk factor for CRC (OR = 3.03; 95%CI = 1.91-2.40; p = 0.003), but only modest association with UC (OR = 1.61; 95%CI = 0.98-2.65; p = 0.059) (Pro/Pro and Pro/Arg genotypes vs. Arg/Arg genotype). We did not find any correlation between genotype distribution of the polymorphism and clinical parameters of CRC, but in UC, Pro/Pro genotype was significantly related to an inflammatory bowel disease family history (OR = 8.0; 95%CI = 1.68-38.08, p = 0.015), and Arg/Pro genotype was significantly associated with the history of disease-related colectomy (OR = 17.77; 95%CI = 0.98-323.34, p = 0.012) and steroid use (OR = 10.14; 95%CI = 2.63-39.12, p = 0.0002). Our data suggest that R72P variant seems to be associated with high risk for development of CRC but carries low risk for development of UC. R72P genotypes might be a useful predictive marker for surgical and medical treatment of UC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20309662     DOI: 10.1007/s12253-010-9255-9

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  35 in total

1.  p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer.

Authors:  Ye Xu; Lihua Yao; Tao Ouyang; Jinfeng Li; Tianfeng Wang; Zhaoqing Fan; Benyao Lin; Youyong Lu; Yuntao Xie
Journal:  Clin Cancer Res       Date:  2005-10-15       Impact factor: 12.531

2.  Two polymorphic variants of wild-type p53 differ biochemically and biologically.

Authors:  M Thomas; A Kalita; S Labrecque; D Pim; L Banks; G Matlashewski
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

3.  Classification of inflammatory bowel disease.

Authors:  J E Lennard-Jones
Journal:  Scand J Gastroenterol Suppl       Date:  1989

4.  Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis.

Authors:  T A Brentnall; D A Crispin; P S Rabinovitch; R C Haggitt; C E Rubin; A C Stevens; G C Burmer
Journal:  Gastroenterology       Date:  1994-08       Impact factor: 22.682

5.  Comparative analysis of histology, DNA content, p53 and Ki-ras mutations in colectomy specimens with long-standing ulcerative colitis.

Authors:  K Holzmann; B Klump; F Borchard; C J Hsieh; A Kühn; V Gaco; M Gregor; R Porschen
Journal:  Int J Cancer       Date:  1998-03-30       Impact factor: 7.396

6.  Increase in colorectal epithelial apoptotic cells in patients with ulcerative colitis ultimately requiring surgery.

Authors:  Chikara Hagiwara; Masanori Tanaka; Hajime Kudo
Journal:  J Gastroenterol Hepatol       Date:  2002-07       Impact factor: 4.029

7.  Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population.

Authors:  Zhong-Zheng Zhu; Ai-Zhong Wang; Hang-Ruo Jia; Xia-Xiang Jin; Xiang-Lei He; Li-Fang Hou; Guanshan Zhu
Journal:  Jpn J Clin Oncol       Date:  2007-05       Impact factor: 3.019

8.  p53 protein expression in ulcerative colitis-associated colorectal dysplasia and carcinoma.

Authors:  N Harpaz; A L Peck; J Yin; I Fiel; M Hontanosas; T R Tong; J N Laurin; J M Abraham; B D Greenwald; S J Meltzer
Journal:  Hum Pathol       Date:  1994-10       Impact factor: 3.466

9.  P53 germ line haplotypes associated with increased risk for colorectal cancer.

Authors:  A Själander; R Birgander; L Athlin; R Stenling; J Rutegård; L Beckman; G Beckman
Journal:  Carcinogenesis       Date:  1995-07       Impact factor: 4.944

Review 10.  p53 polymorphisms: cancer implications.

Authors:  Catherine Whibley; Paul D P Pharoah; Monica Hollstein
Journal:  Nat Rev Cancer       Date:  2009-02       Impact factor: 60.716

View more
  7 in total

1.  Current and future role of serogenomics in ulcerative colitis.

Authors:  Mark H Flasar; Raymond K Cross; David B Doman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-11

2.  The p53 Codon 72 Polymorphism Modifies the Cellular Response to Inflammatory Challenge in the Liver.

Authors:  Julia I-Ju Leu; Maureen E Murphy; Donna L George
Journal:  J Liver       Date:  2013

3.  TP53 codon 72 Arg/Arg polymorphism is associated with a higher risk for inflammatory bowel disease development.

Authors:  Natalia Volodko; Mohamed Salla; Bertus Eksteen; Richard N Fedorak; Hien Q Huynh; Shairaz Baksh
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

4.  The codon 72 polymorphism of p53 regulates interaction with NF-{kappa}B and transactivation of genes involved in immunity and inflammation.

Authors:  Amanda K Frank; Julia I-Ju Leu; Yan Zhou; Karthik Devarajan; Tatiana Nedelko; Andres Klein-Szanto; Monica Hollstein; Maureen E Murphy
Journal:  Mol Cell Biol       Date:  2011-01-18       Impact factor: 4.272

5.  CSF1 is a novel p53 target gene whose protein product functions in a feed-forward manner to suppress apoptosis and enhance p53-mediated growth arrest.

Authors:  Gregory Azzam; Xuting Wang; Douglas Bell; Maureen E Murphy
Journal:  PLoS One       Date:  2013-09-03       Impact factor: 3.240

6.  Risk of Colorectal Carcinoma May Predispose to the Genetic Variants of the GST, CYP450, and TP53 Genes Among Nonsmokers in the Saudi Community.

Authors:  Ikhlas A Sindi; Ahmed O Babalghith; Mohammed T Tayeb; Ahmad H Mufti; Hind Naffadi; Samar N Ekram; Ezzeldin N Elhawary; Munaifah Alenezi; Nasser A Elhawary
Journal:  Int J Gen Med       Date:  2021-04-15

Review 7.  Inflammatory bowel disease.

Authors:  Siavosh Nasseri-Moghaddam
Journal:  Middle East J Dig Dis       Date:  2012-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.